Call Us: +91-9915015108
Iron sucrose, a mineral iron formulation, is prescribed for the treatment of iron deficiency anemia in renal disorder patients. Iron sucrose should be prescribed as a combined therapy. However, Iron sucrose should not be used to treat other forms of anemia. Iron sucrose is an aqueous complex of poly-nuclear iron hydroxide in sucrose solution.
After intravenous administration, Iron sucrose dissociate into iron and sucrose, and the circulating iron is transported an iron complex with transferrin. The complex is then transported to target cells such as erythroid precursor cells. The iron-loaded cells are then maturating with incorporated hemoglobin. This results in a significant increase of serum iron, ferritin and TIBC.
The plasma elimination half-life of Iron sucrose is 6 hours with a total clearance rate of 1.2 L/h, and apparent volume of distribution is 7.9 L. The sucrose is eliminated via urine. In pediatric patients, the terminal half-life is 8 hours with a mean Cmax and AUC of 8545 μg/dl and 31305 hr/μg/dL, respectively. Iron sucrose is not dialyzable.
Iron sucrose is an aqueous complex of poly-nuclear iron (III)-hydroxide in sucrose. Following intravenous administration, Iron is dissociated into iron and sucrose and the iron is transported as a complex with transferring to target cells including erythroid precursor cells. The iron in the precursor cells is incorporated into hemoglobin as the cells mature into red blood cells.
Precautions with hypersensitivity reactions, hypotension and Iron overload. Iron sucrose is contraindicated in patients with iron allergy, hemochromatosis, hepatitis, hypotension and history of many blood transfusions
Iron sucrose may prevent the absorption of oral iron formulation such as ferrous sulfate, ferrous fumarate and ferrous gluconate.
